ALTEOGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 173,700 KRW | 0.00% |
|
+3.15% | +76.35% |
| 2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
| 2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2024 * | 75.5B 54.89M | Sales 2025 * | 156B 113M | Capitalization | 9,204B 6.69B |
|---|---|---|---|---|---|
| Net income 2024 * | 13B 9.45M | Net income 2025 * | 62B 45.07M | EV / Sales 2024 * | 122 x |
| Net cash position 2024 * | 10B 7.27M | Net cash position 2025 * | 63B 45.8M | EV / Sales 2025 * | 58.6 x |
| P/E ratio 2024 * |
676
x | P/E ratio 2025 * |
144
x | Employees | 128 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.48% |
More Fundamentals
* Assessed data
More news
| 1 week | +3.15% | ||
| Current month | -12.01% | ||
| 1 month | -20.87% | ||
| 3 months | +126.76% | ||
| 6 months | +195.41% | ||
| Current year | +76.35% |
1 week
163 600.00
191 600.00
1 month
156 200.00211 500.00
Current year
70 500.00225 500.00
1 year
38 000.00225 500.00
3 years
27 875.00225 500.00
5 years
5 680.56225 500.00
10 years
2 875.00225 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 08-05-12 |
Sang-Woo Kang
DFI | Director of Finance/CFO | 58 | 20-05-31 |
Gyu-Wan Kim
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 08-05-12 |
Jong-In Choi
BRD | Director/Board Member | 59 | 21-03-28 |
In-Young Go
BRD | Director/Board Member | 68 | 21-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.64% | 2 M€ | -14.14% | ||
| 0.02% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 173,700 | 0.00% | 2,896,505 |
| 24-04-25 | 173,700 | -2.58% | 678,762 |
| 24-04-24 | 178,300 | +2.53% | 1,198,718 |
| 24-04-23 | 173,900 | +4.57% | 1,133,270 |
| 24-04-22 | 166,300 | -1.25% | 1,268,393 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Alteogen Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The Company mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
173,700
KRW
Average target price
168,333
KRW
Spread / Average Target
-3.09%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +76.35% | 6.69B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- A196170 Stock
